| About this Abstract |
| Meeting |
2023 TMS Annual Meeting & Exhibition
|
| Symposium
|
Seaborg Institutes: Emerging Topics in Actinide Materials and Science
|
| Presentation Title |
Elucidating the Radiobiology of Alpha Particles in Cancer Therapy |
| Author(s) |
Sandra M. Davern, Miguel Toro-Gonzalez, Amber Bible |
| On-Site Speaker (Planned) |
Sandra M. Davern |
| Abstract Scope |
Targeted alpha therapy utilizes the high-energy deposition and short pathlength of alpha particle emissions to induce DNA double-strand breaks. These are difficult for the cell to repair and, in sufficient amounts, overwhelm DNA repair mechanisms, culminating in cell death. Consequently, their impact on surrounding cells through direct and indirect effects of radiation needs to be evaluated. Clinical trials with Ac-225 (t1/2 = 9.92 days) highlight its potential for eradicating metastatic disease. As targeted alpha therapy becomes accepted and used as a treatment for cancer at earlier stages of disease, it will be important to study the impacts of alpha-emitting radionuclides at a cellular level. Actinium-225 has four alpha emitters in its decay chain, with Bi-213 (t1/2 = 45.6 min) and Fr-221 (t1/2 = 4.9 min) having significant half-lives. Recent assessment of the effect of targeted and untargeted delivery of Ac-225 to breast and ovarian cancer cells will be discussed. |
| Proceedings Inclusion? |
Planned: |
| Keywords |
Nanotechnology, Other, Other |